Related Experiment Video
Updated: Jun 26, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Management of coronary artery disease via simvastatin-loaded novasomes
Amr Gamal Fouad1, Amany Belal2, Olfat Yousef Gushgari3
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Background:
Simvastatin (SMT) offers protection against diabetes mellitus related to coronary artery disease (DM-CAD) because of its cardioprotective, antioxidant, and anti-inflammatory effects. However, its low bioavailability and poor solubility limit its effectiveness.
Objective:
This research aimed to develop and evaluate a nasal simvastatin-loaded novasomes (S-NOV) to enhance the drug's bioavailability, solubility, and effectiveness in treating DM-CAD.
Methods:
The efficacy and bioavailability of the nasal S-NOV formulation were tested in a DM-CAD-induced rat model.
Results:
The optimal S-NOV formulation demonstrated an 8.31-fold increase in bioavailability, a 4.64-fold enhancement in permeability, and a 4.71-fold increase in drug release. The nasal S-NOV formulation showed superior cardioprotective and antioxidant effects compared to oral SMT in various biomarkers, including lactate dehydrogenase, glutathione, and catalase. Histopathological and toxicology studies confirmed that the nasal S-NOV formulation was effective and safe.
Conclusion:
These findings suggest that nasal S-NOV formulation could be a viable and safe therapy for DM-CAD.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Angina IV: Management
Atherosclerosis IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures